Clinical Trial Update: Her2-positive Lung Cancer Treated With Dedicated Drug [Phase 2]

View source ↗

Summary

A Phase 2 trial update for a HER2-positive non-small cell lung cancer treatment is reported as completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Dedicated Drug

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Stage III | Phase 2 | Status: COMPLETED